Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Zynex Inc (ZYXI)

Zynex Inc (ZYXI)
2.41 -0.11 (-4.37%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 2.30 -0.11 (-4.56%) 04/25/25
News & Headlines for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Why Zynex Plunged Today

Earnings and guidance disappointed, but the pullback could be an opportunity.

ZYXI : 2.41 (-4.37%)
Zynex Recognized in Top 100 Healthcare Technologies Companies for Second Year in a Row

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex, Inc Sets Third Quarter 2023 Earnings Call

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex to Present at the Cantor Global Healthcare Conference

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex Announces Share Repurchase Program

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex to Present at the H.C. Wainwright Global Investment Conference

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex Announces 1 Millionth Patient Milestone

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex, Inc Announces New Therapy Products

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex, Inc Founder and CEO Thomas Sandgaard to participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar on August 3rd at 12:15 PM ET

/PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex, Inc. Sets Second Quarter 2023 Earnings Call

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex, Inc. (NASD: ZYXI) Wins 2023 National Top Workplaces Award in the Manufacturing Industry Category

/PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex Reports Preliminary Second Quarter 2023 Results

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex, Inc. Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

/PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Why Shares of Zynex Are Up Wednesday

After buying back $30 million in stock over the past 12 months, the company is now planning a $10 million stock buyback.

ZYXI : 2.41 (-4.37%)
Zynex Announces Share Buyback Program

/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices...

ZYXI : 2.41 (-4.37%)
Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering

/PRNewswire/ -- Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), announced today the pricing of its previously announced private offering of $52.5 million aggregate...

ZYXI : 2.41 (-4.37%)
Zynex Announces Update Regarding Previously Announced Offerings

/PRNewswire/ -- Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), today announced that Thomas Sandgaard, its Chief Executive Officer (the "Selling Stockholder"), has...

ZYXI : 2.41 (-4.37%)
Zynex Announces Proposed Secondary Public Offering of Common Stock

/PRNewswire/ -- Zynex, Inc. ("Zynex" or "the Company") (Nasdaq: ZYXI), today announced the commencement of an underwritten public offering of 2,000,000 shares...

ZYXI : 2.41 (-4.37%)

Barchart Exclusives

Used Tesla Prices Are Plunging. Is This the Final Nail in the Coffin for TSLA Stock?
Tesla’s resale collapse and China slump hint at deeper cracks in demand. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.